First cohort dosed with potential treatment for Von Willebrand disease
Ella Day | April 11, 2025 | News story | Research and Development | Haematology, Hemab Therapeutics, Richmond Pharma, Von Willebrand Disease, bleeding disorder
UK-based clinical trials company, Richmond Pharmacology, has completed the first stage of Velora Pioneer, a phase 1/2 clinical trial investigating Hemab Therapeutic’s HMB-002, a potential subcutaneous therapy for Von Willebrand disease (VWD).
VWD is the most common inherited bleeding disorder, affecting over 12,000 people in the UK. It is characterised by defects in von Willebrand Factor (VWF) and symptoms involve bleeding episodes. Despite its prevalence and detrimental impact on quality of life, current treatment options are limited as they reactively manage symptoms and do not address the underlying condition.
HMB-002 is a monovalent antibody which focuses on the underlying cause of VWD by increasing levels of VWF and Factor VIII. The Velora Pioneer study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of HMB-002 in individuals with VWD.
Hemab develops prophylactic therapeutics for underserved bleeding and thrombotic disorders. The company’s preclinical data for the potential therapy was presented at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Milan, Italy in February 2025.
Principal investigator at Richmond, Ulrike Lorch, commented: “We are delighted to be involved in a trial which may offer hope, not just for future generations of patients, but for those currently experiencing the day-to-day impacts of this often-debilitating condition.”
Benny Sorensen, chief executive officer of Hemab Therapeutics, said: “We believe HMB-002 can become a new back-bone therapy for all types of VWD.”
Ella Day
11/4/25
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World …
